CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 154 enrolled
Drug / intervention
indacaterol/glycopyrrolate +2 moredrug
Likely dose
indacaterol/glycopyrrolate 50 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00570778
NCT00570778Phase 2Completed
CompareCT.gov

A Randomized, Double-blind, Placebo Controlled, Multicentre Study to Determine the Effect of QVA149 on Lung Function in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Novartis Pharmaceuticals·interventional·Posted Dec 11, 2007·Updated Jul 26, 2018

In Brief

A Phase 2 clinical trial evaluating indacaterol/glycopyrrolate, indacaterol, and 1 other intervention for Chronic Obstructive Pulmonary Disease (COPD). Completed, enrolled 154 participants across 22 sites in 5 countries.

Detailed Summary

This study will evaluate the safety and efficacy of QVA149 in patients with moderate to severe COPD.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Obstructive Pulmonary Disease (COPD)
CountriesBelgium, Canada, Germany, Netherlands, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 11, 2007
Enrollment StartDec 1, 2007
Primary CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 18.6 years ago

Interventions

indacaterol/glycopyrrolatedrug

Inhalation capsule indacaterol/glycopyrrolate 300/50 μg inhaled once daily via a single dose dry powder inhaler for 7 days.

indacateroldrug

Inhalation capsule indacaterol supplied as 300 μg capsules inhaled once daily via a single dose dry powder inhaler for 7 days.

placebodrug

Placebo inhalation capsules inhaled once daily via a single dose dry powder inhaler for 7 days.